Funding: Blinding peer review
Concealing the identity of the principal investigator only partially closes the success gap between white and African American or Black researchers in NIH grant applications.
- Department of Psychiatry and the Skaggs School of Pharmacy, University of California, San Diego, United States
Every year, approximately 55,000 research grant applications are submitted to the US National Institutes of Health (NIH); of those only 11,000 will be selected for funding. NIH-funded research drives major advances in scientific knowledge, medicine and healthcare, helping to improve health, to reduce morbidity and to create economic innovation. Yet, how this funding is distributed is increasingly coming under scrutiny.
In particular, research shows that applications spearheaded by principal investigators who identify as African American or Black (AAB) do not get funded as often as those led by white researchers. From 2000 to 2006, for instance, Research Project Grant (R01) applications by AAB investigators were 42% less successful than those led by white researchers (Ginther et al., 2011). When the report highlighting this gap was first published in 2011, the Director of the NIH asserted that “the situation [was] not acceptable” (Corbyn, 2011); yet a similar 40 % reduction in success rate was reported for applications with AAB principal investigators submitted from 2011 to 2015 (Hoppe et al., 2019). AAB leaders were more likely to propose investigating questions that were less often awarded money, but they were also less likely to be funded regardless of grant topic.
Overall, this body of work suggests that AAB scientists have unequitable access to public resources, hindering the advance of knowledge – especially on health care topics of interest for communities of color (Dzirasa, 2020; Gilpin and Taffe, 2021; Harnett, 2020; Stevens et al., 2021; Taffe and Gilpin, 2021). These disparities shed light on biases that may contaminate the grant-awarding mechanism, spurring interest into whether the process could be improved. Now, in eLife, Bruce Reed and colleagues at the NIH/Center for Scientific Review – including Richard Nakamura as first author – report the impact of reviewer blinding on the funding gap (Nakamura et al., 2021).
Typically, each NIH application is first evaluated in depth by three peer scientists, who provide an initial ‘overall-impact’ score which is averaged to rank the submissions. A panel of 20–30 researchers then assembles to discuss the top half of the applications assigned to them; together, they vote on a final overall-impact score for each of these projects, following a discussion led by the three assigned reviewers. Finally, these scores are used by the 24 NIH Institutes and Centers that issue the grants to decide which projects to fund (Kienholz and Berg, 2013). Initial peer review therefore plays a major role in determining which applications will receive a grant by providing an all-critical preliminary impact score. Many have therefore proposed that blinding these reviewers to the identity of the applicants could help to potentially eliminate the disparity between white and AAB investigators.
To explore this question, Nakamura et al. obtained 400 R01 applications with AAB principal investigators submitted and reviewed in 2014–2015, as well as two comparison sets of 400 applications with white investigators. One of these two sets was randomly selected from the 26,000 applications submitted in the same period; the other was created by ensuring that the applications matched those with AAB principal investigators on several characteristics, including the preliminary impact score from the assigned reviewers. The team removed any identity information from the proposals. Both anonymized and original, unredacted applications were then peer-reviewed by different sets of researchers.
Results showed that anonymizing the applications reduced the scores for projects led by white investigators, but this manipulation did not change the scores of applications from AAB researchers. Overall, the reduction in white investigators’ scores only closed the AAB-white gap by about half. Yet, several methodological issues may limit how well these results could translate to actual NIH review processes.
First, reviewers did not meet in panels to discuss applications and vote final scores; a critical part of the NIH reviewing process was therefore not duplicated, and the impact of blinding this step cannot be determined. Second, Nakamura et al. report that 22% of reviewers ‘broke the blind’ by correctly identifying the specific principal investigator or research group leading the anonymized application. Merely removing direct identifiers from proposals may therefore not be sufficient to blind review. Finally, scores were not always replicated between the original and study reviews – they were improved for white investigators in the group matching AAB applicants’ scores. This discrepancy could imply that the reviews conducted for the study might have been done differently than during the original process.
Importantly, the work by Nakamura et al. shows that changing NIH grant evaluation to blinded review will have limited impact, one that will take place primarily through reducing the advantage of non-anonymized proposals for white investigators. White researchers from one of the groups received different scores in the study, compared to the original review, which clearly suggests that review outcomes at the NIH may not reflect objective and highly repeatable assessments of merit.
This study has critical implications for fixing the NIH funding disparity first identified in the 2011 Ginther report. So many have proposed that blinding review is a simple solution; Nakamura et al. have shown that this would be insufficient. This work, combined with identified disparities in funding of topics (Hoppe et al., 2019), should re-orient the NIH away from trying to identify singular causes, and towards applying direct fixes with immediate impact.
References
-
Toward an anti-racist approach to biomedical and neuroscience researchThe Journal of Neuroscience 41:8669–8672.https://doi.org/10.1523/JNEUROSCI.1319-21.2021
-
Race, ethnicity, and NIH research awardsScience 333:1015–1019.https://doi.org/10.1126/science.1196783
Article and author information
Author details
Publication history
Copyright
© 2021, Taffe
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,565
- views
-
- 72
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Funding: Blinding peer review
eLife 10:e74744.
https://doi.org/10.7554/eLife.74744
Further reading
-
- Cell Biology
Overnutrition engenders the expansion of adipose tissue and the accumulation of immune cells, in particular, macrophages, in the adipose tissue, leading to chronic low-grade inflammation and insulin resistance. In obesity, several proinflammatory subpopulations of adipose tissue macrophages (ATMs) identified hitherto include the conventional ‘M1-like’ CD11C-expressing ATM and the newly discovered metabolically activated CD9-expressing ATM; however, the relationship among ATM subpopulations is unclear. The ER stress sensor inositol-requiring enzyme 1α (IRE1α) is activated in the adipocytes and immune cells under obesity. It is unknown whether targeting IRE1α is capable of reversing insulin resistance and obesity and modulating the metabolically activated ATMs. We report that pharmacological inhibition of IRE1α RNase significantly ameliorates insulin resistance and glucose intolerance in male mice with diet-induced obesity. IRE1α inhibition also increases thermogenesis and energy expenditure, and hence protects against high fat diet-induced obesity. Our study shows that the ‘M1-like’ CD11c+ ATMs are largely overlapping with but yet non-identical to CD9+ ATMs in obese white adipose tissue. Notably, IRE1α inhibition diminishes the accumulation of obesity-induced metabolically activated ATMs and ‘M1-like’ ATMs, resulting in the curtailment of adipose inflammation and ensuing reactivation of thermogenesis, without augmentation of the alternatively activated M2 macrophage population. Our findings suggest the potential of targeting IRE1α for the therapeutic treatment of insulin resistance and obesity.
-
- Cell Biology
Understanding how the brain controls nutrient storage is pivotal. Transient receptor potential (TRP) channels are conserved from insects to humans. They serve in detecting environmental shifts and in acting as internal sensors. Previously, we demonstrated the role of TRPγ in nutrient-sensing behavior (Dhakal et al., 2022). Here, we found that a TRPγ mutant exhibited in Drosophila melanogaster is required for maintaining normal lipid and protein levels. In animals, lipogenesis and lipolysis control lipid levels in response to food availability. Lipids are mostly stored as triacylglycerol in the fat bodies (FBs) of D. melanogaster. Interestingly, trpγ deficient mutants exhibited elevated TAG levels and our genetic data indicated that Dh44 neurons are indispensable for normal lipid storage but not protein storage. The trpγ mutants also exhibited reduced starvation resistance, which was attributed to insufficient lipolysis in the FBs. This could be mitigated by administering lipase or metformin orally, indicating a potential treatment pathway. Gene expression analysis indicated that trpγ knockout downregulated brummer, a key lipolytic gene, resulting in chronic lipolytic deficits in the gut and other fat tissues. The study also highlighted the role of specific proteins, including neuropeptide DH44 and its receptor DH44R2 in lipid regulation. Our findings provide insight into the broader question of how the brain and gut regulate nutrient storage.
